How to Plan a Rapid Review: Methods, Shortcuts and Transparent Reporting

MetaSyn Academy guide to plan a rapid review, illustrating the decisions documented by Rapid review protocol template
Academic methodology guideEvidence checked: 9 August 2026

A rapid review is not a systematic review with a few boxes deleted. It is an evidence-synthesis process in which selected methods are deliberately simplified or omitted so that evidence can reach a decision in time. That makes the planning problem harder, not easier: the team has to decide which safeguards can be streamlined, which should remain intact, and how the resulting uncertainty will be explained to the people using the review.1,2

The field has moved away from treating rapid review as one uniform recipe. Cochrane’s updated guidance contains 24 recommendations for rapid reviews of effectiveness, but it explicitly allows teams to apply all or some restrictions according to the topic, timeframe and resources. Separate guidance now exists for rapid qualitative evidence synthesis and for rapid scoping, mapping and evidence-and-gap-map work. The common principle is transparent adaptation; the exact shortcut package depends on the underlying review design.2,11,12

Keep the taxonomy elsewhere. This guide assumes you have already decided that rapid conduct is being considered. If the underlying evidence-synthesis design is still unclear, resolve that first. Rapid is a mode of conduct; it does not erase the methodological requirements of the systematic, scoping, overview, qualitative or other synthesis underneath it.1

Appropriateness comes before acceleration

A genuine deadline matters because rapid review exists to support decisions that cannot always wait for a conventional review timeline. But the date on the calendar is only one part of the appropriateness decision. Current methods guidance asks what decision will be made, whether the question is urgent or high priority, the cost of waiting, whether the findings can actually be used on time, how complex the question is, and whether the team has enough review expertise and resources to produce something interpretable.3

This is why a thesis submission date and a reimbursement deadline are methodologically different, even when both are six weeks away. In the reimbursement case, a defined external decision may proceed with or without synthesized evidence. In the thesis case, the deadline is largely a property of the research project. It may justify narrowing the research question or choosing a feasible study design, but it does not by itself establish that systematic-review safeguards should be relaxed. The same is true of convenience, small-team size or a desire for faster publication. Those constraints are real, but the rapid-review appropriateness literature does not treat them as sufficient reasons on their own.3

Rapid review appropriateness triangle Three aligned panels represent decision urgency, scope feasibility and methodological capacity, converging on a central rapid-review decision. Decision urgency What happens if evidence arrives too late? Scope feasibility Can the question be answered inside the time available? Methods capacity Are expertise, tools and verification available? Rapid conduct is plausible Only then choose which methods can be adapted responsibly.
Figure 1. Speed is only one axis. A rapid review becomes plausible when the evidence is needed for a real decision, the question can be scoped to the deadline, and enough methodological capacity remains to conduct and verify the review.

There is no universal shortcut package

Rapid reviews vary because the expensive parts of evidence synthesis vary. For one question, screening 20,000 records may dominate the workload. For another, the search is manageable but outcome extraction is complex. A third may have only six studies but require difficult risk-of-bias judgments and a network meta-analysis. Applying the same set of shortcuts to all three reviews would be convenient, but methodologically weak.

The current search guidance makes this point directly. Search acceleration can come from spending less time conducting searches or from reducing the size of the result set. Because screening often consumes more resources than running the database search itself, the authors recommend investing effort in search planning and involving an information specialist so that a smaller set of sources can still be chosen intelligently and the strategy can balance sensitivity with precision.4 A narrower search is therefore not automatically a faster review if it creates a poorly targeted result set or forces the team to compensate later.

Retain first

Safeguards with direct decision value

Risk-of-bias assessment, certainty assessment for effectiveness questions, and a synthesis capable of answering the decision question should not disappear automatically. Current rapid-review guidance instead describes ways to narrow the outcome scope or reduce reviewer duplication while preserving the underlying methodological function.2,5,7

Adapt deliberately

Workload that can be compressed

Database coverage, supplementary searching, reviewer duplication, extraction breadth and secondary analyses can sometimes be reduced. The important question is not whether a shortcut exists but whether the saved effort is worth the residual risk for this decision.

The literature search is often where teams are most tempted to impose a simple rule such as “MEDLINE only,” “English only,” or “last five years.” Current guidance is more careful. For rapid reviews of effectiveness focused on randomized trials, Cochrane provides design-specific database recommendations; the broader rapid-search paper advises a small number of relevant information sources selected with an information specialist. Those recommendations should not be converted into one universal database count for education, environmental policy, qualitative synthesis or every other rapid product.2,4

Language restriction illustrates why context matters. A meta-epidemiological study of 59 Cochrane intervention reviews found that excluding non-English publications had little effect on the conclusions in that particular sample, even though 31 studies were lost from the evidence base.18 That is useful empirical evidence, but it is not permission to assume English-only searching is harmless in every topic. The result came from clinical intervention reviews, and excluded studies were often small. In a global policy question, infectious-disease topic, traditional medicine review or LMIC-focused synthesis, the representation consequences may be much larger.

Date restrictions need the same discipline. A natural starting point can exist when a technology was introduced, a law changed, or an existing high-quality review provides a verified search endpoint. “The last five years” is different: it is a workload shortcut with no intrinsic relation to the evidence question. If the review uses such a limit, the protocol should say what earlier evidence may be lost and why the decision-maker accepted that trade-off.

RestrictionPotential reasonWhat can go wrongBetter protocol wording
Fewer information sourcesReduce retrieval and screening workload.Relevant studies may exist only in omitted sources; magnitude depends on topic and design.Name the retained sources, why they are high yield, and what supplementary method will check for obvious gaps.
English onlyTranslation capacity is unavailable inside the decision window.Non-English evidence and regional perspectives may be systematically underrepresented.State the operational constraint, empirical uncertainty and populations/regions most likely to be affected.
Date limitA technology, policy or previous review provides a defensible start date.Arbitrary recency limits can remove foundational or long-term evidence.Connect the date to an external event or verified prior search, not to convenience.
Reduced grey literatureFocus on sources most likely to alter the decision.Regulatory, policy or unpublished evidence may be missed and publication-bias concerns may increase.Specify which grey sources remain essential for this topic and which are being omitted.

Screening is where speed creates a measurable exclusion risk

Screening is one of the few rapid-review steps with a clear empirical demonstration of what can be lost. Gartlehner and colleagues randomized 280 participants to screen abstracts from two review topics. Single-reviewer abstract screening had a sensitivity of 86.6% and missed 13% of relevant studies; dual screening missed about 3%.6 The finding is important because it quantifies a real error mechanism, but it should not be turned into a universal “13% penalty.” Reviewer expertise, topic complexity, eligibility criteria, calibration and software can all change performance.

Cochrane’s updated guidance therefore recommends partial dual independent screening and agreement assessment before moving to single screening. It gives a proportion such as 20% and agreement such as κ≈0.8 as examples.2 The methodological idea is more durable than the numbers: calibrate the team on enough records to understand disagreement, predefine what acceptable agreement means for this project, and preserve a mechanism for detecting false exclusions. If reviewers disagree substantially during calibration, acceleration should not proceed simply because the deadline remains unchanged.

Screening acceleration ladder Four vertically aligned screening approaches move from dual independent screening to unverified single screening, with verification decreasing and false-exclusion concern increasing. Screening acceleration should remove redundancy gradually Dual independent screening Maximum reviewer redundancy Best protection against false exclusion Partial dual calibration Then single screen if agreement is acceptable Cochrane rapid-review option Single reviewer + exclusion check Second reviewer focuses on likely false exclusions Less redundancy; more dependence on first reviewer Unverified single screening Fastest staffing model Highest false-exclusion concern
Figure 2. Screening shortcuts are not binary. A rapid protocol can reduce reviewer duplication while retaining calibration and verification, rather than jumping directly from full dual screening to unverified single screening.

Extraction can be streamlined without making one person the only line of defence

Current rapid-review team guidance recommends a piloted extraction form, a minimal set of required data, one person extracting and another checking for correctness and completeness.5 This differs from simply assigning the entire task to one reviewer. Verification matters most for data that directly feed the result: effect estimates, denominators, variance measures, outcome definitions and information that affects eligibility or risk-of-bias judgments.

A protocol can also reduce extraction breadth. If the commissioner needs five decision-critical outcomes, extracting dozens of secondary outcomes because they happen to appear in the papers may waste the rapid timeline. The safe restriction is prospective: identify the variables required to answer the question, explain why other fields are not needed, and avoid deciding what is “important” only after seeing which results are statistically attractive.

Risk of bias and certainty do not disappear because the review is rapid

For rapid reviews of effectiveness, Cochrane retains risk-of-bias assessment. The accelerated staffing model is one assessor with another person verifying the judgments, and outcome-level assessment may be focused on outcomes most important for decision-making.2,5 This is a useful example of a principled shortcut: it removes reviewer duplication while retaining the evaluative function that makes the effect estimate interpretable.

Certainty assessment is slightly different. The dedicated guidance recommends full GRADE for Cochrane rapid reviews if time and resources allow. When full implementation is not feasible, teams can focus on the main intervention and comparator, restrict ratings to critical benefits and harms, use one reviewer with second-person verification, or reuse trustworthy certainty ratings from an incorporated high-quality systematic review.7 The right conclusion is not “GRADE is mandatory in every rapid review,” nor is it “GRADE can be omitted because the review is rapid.” The protocol should state what level of certainty assessment the decision needs, what is feasible, and what users lose if it is absent.

The underlying design still matters. Rapid scoping reviews are not rapid effectiveness reviews; formal risk-of-bias or GRADE assessment is not automatically required merely because the word rapid appears in the title. Rapid qualitative evidence synthesis uses different appraisal and confidence concepts. This is why an adaptation template must branch by design rather than treating one health-intervention workflow as the definition of rapid evidence synthesis.11,12

Meta-analysis is not the enemy of speed

Another common misconception is that a rapid review should avoid meta-analysis. The updated Cochrane guidance says to consider meta-analysis when appropriate and resources permit, and it applies the same methodological standards used in a systematic review.2 The evidence-synthesis guidance makes the same distinction: every rapid review should synthesize the evidence, but the form of synthesis depends on the studies and the question.8

The statistical calculation is often not the slow part. Harmonizing outcome definitions, checking extracted numbers, resolving multiplicity, deciding whether studies are clinically comparable and planning heterogeneity analyses can consume much more time. If those tasks are required to answer the decision question, removing the meta-analysis does not necessarily produce a better or faster synthesis. Conversely, forcing a meta-analysis into heterogeneous data because a commissioner wants one number is equally indefensible. Rapid status changes the timetable, not the conditions under which pooling is meaningful.

Decision-makers should shape the question, not dictate unsafe methods

Rapid reviews are closely connected to knowledge users because their value depends on reaching a decision in time. Cochrane’s knowledge-user guidance describes opportunities to involve patients and public partners, healthcare providers and policymakers during planning, conduct and knowledge translation. It also acknowledges that meaningful involvement consumes time and resources.9 The practical implication is not that every rapid review needs every stakeholder group. It is that the people who will use the review should be identifiable, and the team should decide where their input improves decision relevance.

Methodological authority needs a separate line. A commissioner can say that evidence is required by 15 October, that mortality and hospital admission are the outcomes driving the policy, and that a 300-page report would be unusable. Those are legitimate decision requirements. The commissioner should not simply declare that risk-of-bias assessment must be removed or that one database is enough. The review team has to translate the deadline into a defensible package of adaptations.

Rapid review adaptation governance A two-column governance diagram shows the commissioner defining decision need and deadline, the methods team assessing adaptations, and a shared negotiation area producing an agreed protocol and documented residual limitations. Decision-maker / commissioner Defines the decision, deadline, priority outcomes and usable product. Review methods team Assesses feasibility, evidence loss, verification and design-specific standards. Negotiate trade-offs Narrow scope before removing critical safeguards. Agreed protocol: adaptations + safeguards + residual limitations If no defensible package fits the deadline, renegotiate scope or time.
Figure 3. The commissioner owns the decision context; the review team owns methodological assessment. The protocol records the negotiated solution rather than allowing a deadline to silently determine the methods.

The adaptation matrix is an audit trail, not a risk calculator

The strongest rapid-review protocol is not the one with the largest list of shortcuts. It is the one in which each departure from the standard method can be traced to a reason. A practical matrix can record the review step, planned adaptation, rationale, anticipated consequence and mitigation. This corresponds closely to Cochrane’s recommendation to describe the selected rapid approach, restricted methods and potential limitations so readers can understand how those restrictions affect interpretation.2

What the matrix should not do is assign a fabricated “low,” “moderate” or “high” bias score to every shortcut. The evidence base is too uneven. Single-reviewer abstract screening has direct empirical accuracy data, but the magnitude of evidence loss from omitting a particular database or grey-literature source depends heavily on the topic. Some restrictions may miss studies without materially changing a conclusion; others can erase a whole regional evidence base. A descriptive consequence such as “may reduce comprehensiveness; magnitude uncertain” is more honest than an unsupported red score.

AdaptationEvidence statusReasonable interpretationDo not claim
Single-reviewer abstract screeningDirect randomized evidence plus methods guidance.Can reduce reviewer workload but increases false-exclusion risk; calibration or verification can preserve some redundancy.6That every review will miss exactly 13% of eligible studies.
Smaller source setMethods guidance and database-coverage research; effect varies by topic.Can reduce retrieval and screening burden when sources are chosen deliberately.4,19That a fixed number of databases is universally sufficient.
English-only inclusionMeta-epidemiological evidence exists for clinical intervention reviews.May have little effect in some intervention reviews but can reduce representation and is not automatically transferable to other fields.18That language restriction is bias-free.
One extractor + verifierCurrent Cochrane rapid-review methods recommendation.Removes independent duplication while retaining an error-checking layer.5That verification can safely be removed without consequence.
Focused GRADEDedicated certainty guidance.Can prioritize main comparisons and critical outcomes when full implementation is infeasible.7That rapid-review status itself lowers or replaces certainty assessment.

Transparent reporting is part of the method

Reporting is especially important in a rapid review because the reader cannot infer which parts of the conventional process were compressed. PRISMA 2020 remains the general reporting standard for systematic reviews. PRISMA-RR is still listed by EQUATOR as under development as of 9 August 2026, so it should not be cited as a finalized checklist.14,16

In the meantime, Stevens and colleagues have published interim rapid-review reporting guidance. The paper identifies a minimum set of six rapid-review-specific items in addition to existing guidance, including methods-related items and publication-ethics considerations. Among the important methodological points are reporting a priori iterative methods, describing what distinguishes the rapid review from a conventional systematic review, and explaining knowledge-user involvement.13 The final journal issue is 2025 even though the article was published online in 2024, so citation dates should be handled carefully.

This is why protocol planning and reporting should be connected. If the protocol records every restriction, rationale, mitigation and planned iterative rule, the final report does not have to reconstruct those decisions from memory. Deviations can be added as they occur. The result is not a claim of “PRISMA-RR compliance.” It is a transparent account of what was planned, what changed and what the rapid approach means for interpretation.

Sometimes the right rapid-review decision is to renegotiate

Some deadlines cannot support the question originally requested. An extremely broad effectiveness question may require too many searches, too much screening or too many outcomes. A commissioner may request a one-database search, unverified screening, no appraisal and no certainty assessment because all four appear to save time. The correct response is not automatically to accept the package and place a limitation paragraph at the end.

Methodologically, narrowing scope is often safer than removing independent safeguards across every stage. A team can prioritize the population, intervention, comparison or outcomes that actually drive the decision. It can build on a current high-quality systematic review rather than starting again. It can negotiate a staged product, with a rapid initial synthesis followed by a fuller update. Or it can extend the deadline. The appropriateness framework asks reviewers to consider the risk of an incomplete rapid synthesis against the risk of no synthesis and the cost of waiting.3

If no defensible method fits the requested timeline, the team should say so. That conclusion is not a failure of rapid review. It is the point of methodological planning.

Different decisions justify different adaptations

ScenarioMethod worth retainingPlausible accelerationAdaptation to resist
Ministry needs evidence on an outbreak intervention in three weeks.Risk-of-bias assessment for critical outcomes.Prioritize critical outcomes; calibrate screening then reduce reviewer duplication; focus supplementary searches on high-yield sources.Dropping appraisal and certainty simply because the deadline is short.
Guideline panel needs an effectiveness update in four months.Meta-analysis and GRADE if the evidence supports pooling.Build from the previous trustworthy review; limit new extraction to decision-critical outcomes.Replacing quantitative synthesis with narrative text solely to appear rapid.
HTA body needs a reimbursement decision.Decision-relevant grey/regulatory evidence and appraisal.Limit secondary outcomes and low-yield supplementary searching.English-only or publication-type restrictions that exclude evidence central to the technology’s regulatory history without analysis.
Education ministry needs a broad picture of AI use in schools.Underlying scoping/mapping logic.Use rapid Big Picture Review guidance; prioritize high-level charting fields and efficient screening.Importing effectiveness-review GRADE and RoB requirements into a descriptive map.
Health system needs rapid qualitative evidence on implementation barriers.Qualitative synthesis logic and confidence method appropriate to the QES.Use rapid QES sampling/data-reduction guidance.Calling a descriptive list of themes a qualitative synthesis without a coherent specialist method.
Researcher has an eight-week thesis deadline but no external decision need.Method appropriate to the research question.Narrow the question or choose a feasible design.Calling the project a rapid review solely to justify weaker methods.

Where the protocol template fits

The paired Rapid review protocol template turns the principles in this guide into an audit trail. It starts with the decision need and underlying synthesis design, then asks the team to record the method retained or adapted, why the adaptation is necessary, the consequence that may remain and the verification used to reduce avoidable error. It also separates prospective adaptations from later protocol deviations.

The tool deliberately does not generate a quality percentage or label the review “valid.” There is no validated equation that converts a set of rapid-review shortcuts into a probability of correctness. A protocol can be complete and still contain a method that needs expert reconsideration. The safe endpoint is therefore ready for methodological review, not certified.

Questions about rapid-review planning

How fast does a review have to be to count as rapid?

There is no universal duration threshold. Rapid reviews are usually time-constrained, but current methods work emphasizes the deliberate abbreviation of review methods and decision context rather than a fixed number of weeks or months.3,20

Can I use Cochrane’s 24 recommendations for a rapid scoping review?

Not wholesale. The 24 recommendations were developed for rapid reviews of effectiveness. Rapid scoping, mapping and evidence-and-gap-map work now has dedicated guidance, and the rapid adaptation must respect the standard methodology of the underlying Big Picture Review.2,11

Is one database enough for a rapid review?

No universal answer exists across all rapid designs. Current rapid-search guidance recommends selecting a small number of high-yield sources with information-specialist input; Cochrane effectiveness guidance provides more specific recommendations for RCT-focused searches. A one-database plan needs unusually strong topic-specific justification and a clear account of what may be missed.4

Does single-reviewer screening always miss 13% of studies?

No. Thirteen percent was the result of one randomized screening study across two reference topics. It shows that false exclusions are a real risk, not that every rapid review has the same loss rate.6

Should a rapid effectiveness review omit GRADE?

Not automatically. Current Cochrane guidance recommends full GRADE if time and resources allow and describes focused, verified adaptations when full implementation is infeasible.7

Do rapid reviews have to involve patients or policymakers?

Knowledge-user involvement is strongly encouraged because rapid reviews are designed around time-sensitive decision needs, but the dedicated guidance does not make every stakeholder group a definitional prerequisite. The relevant users and feasible mode of involvement depend on the review context.9

Is PRISMA-RR the current reporting checklist?

No. PRISMA-RR remains under development. PRISMA 2020 and the published interim rapid-review reporting guidance are the relevant current sources, with PRIOR added when the underlying product is an overview of reviews.13,14,16

A rapid review is strongest when the trade-offs are visible before the results

Rapid review planning is not a search for the fastest possible method. It is a negotiation between a real decision deadline and the minimum methodological work needed to make the evidence interpretable. Some standard methods can be retained. Some can be staffed differently. Some can be narrowed to critical outcomes. Some restrictions may be defensible only for a particular topic. Others create uncertainty that cannot be quantified in advance.

The protocol should make those choices visible before the team knows what the studies say. That is what separates deliberate acceleration from post hoc convenience. When the review is published, readers should be able to see the same chain: why rapid conduct was chosen, what changed from the full method, how errors were mitigated, what limitations remain, and how much confidence the decision-maker should place in the result.

Methodological guidance and empirical evidence

  1. Nussbaumer-Streit B, Campbell F, Munn Z, et al. Overview of evidence synthesis types and modes. J Clin Epidemiol. 2025;187:111970. https://doi.org/10.1016/j.jclinepi.2025.111970
  2. Garritty C, Hamel C, Trivella M, et al. Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness. BMJ. 2024;384:e076335. https://doi.org/10.1136/bmj-2023-076335
  3. Garritty C, Nussbaumer-Streit B, Hamel C, Devane D; Cochrane Rapid Reviews Methods Group. Rapid reviews methods series: assessing the appropriateness of conducting a rapid review. BMJ Evid Based Med. 2025;30(1):55-60. https://doi.org/10.1136/bmjebm-2023-112722
  4. Klerings I, Robalino S, Booth A, et al.; Cochrane Rapid Reviews Methods Group. Rapid reviews methods series: guidance on literature search. BMJ Evid Based Med. 2023;28(6):412-417. https://doi.org/10.1136/bmjebm-2022-112079
  5. Nussbaumer-Streit B, Sommer I, Hamel C, et al.; Cochrane Rapid Reviews Methods Group. Rapid reviews methods series: guidance on team considerations, study selection, data extraction and risk of bias assessment. BMJ Evid Based Med. 2023;28(6):418-423. https://doi.org/10.1136/bmjebm-2022-112185
  6. Gartlehner G, Affengruber L, Titscher V, Noel-Storr A, Dooley G, Ballarini N, König F. Single-reviewer abstract screening missed 13 percent of relevant studies: a crowd-based, randomized controlled trial. J Clin Epidemiol. 2020;121:20-28. https://doi.org/10.1016/j.jclinepi.2020.01.005
  7. Gartlehner G, Nussbaumer-Streit B, Devane D, et al.; Cochrane Rapid Reviews Methods Group. Rapid reviews methods series: guidance on assessing the certainty of evidence in rapid reviews. BMJ Evid Based Med. 2024;29(1):50-54. https://doi.org/10.1136/bmjebm-2022-112111
  8. King VJ, Nussbaumer-Streit B, Shaw E, et al.; Cochrane Rapid Reviews Methods Group. Rapid reviews methods series: considerations and recommendations for evidence synthesis in rapid reviews. BMJ Evid Based Med. 2024;29(6):419-422. https://doi.org/10.1136/bmjebm-2023-112617
  9. Garritty C, Tricco AC, Smith M, et al.; Cochrane Rapid Reviews Methods Group. Rapid Reviews Methods Series: involving patient and public partners, healthcare providers and policymakers as knowledge users. BMJ Evid Based Med. 2024;29(1):55-61. https://doi.org/10.1136/bmjebm-2022-112070
  10. Affengruber L, Nussbaumer-Streit B, Hamel C, et al.; Cochrane Rapid Reviews Methods Group. Rapid review methods series: guidance on the use of supportive software. BMJ Evid Based Med. 2024;29(4):264-271. https://doi.org/10.1136/bmjebm-2023-112530
  11. Campbell F, Sutton A, Pollock D, et al. Rapid reviews methods series: guidance on rapid scoping, mapping and evidence and gap map (‘Big Picture Reviews’). BMJ Evid Based Med. 2025;30(4):268-277. https://doi.org/10.1136/bmjebm-2023-112389
  12. Booth A, Noyes J, Flemming K, et al. Rapid reviews methods series: guidance on rapid qualitative evidence synthesis. BMJ Evid Based Med. 2024;29(3):194-200. https://doi.org/10.1136/bmjebm-2023-112620
  13. Stevens A, Hersi M, Garritty C, et al.; Cochrane Rapid Reviews Methods Group. Rapid review method series: interim guidance for the reporting of rapid reviews. BMJ Evid Based Med. 2025;30(2):118-123. Published online 2024. https://doi.org/10.1136/bmjebm-2024-112899
  14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
  15. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. https://doi.org/10.1136/bmj.g7647
  16. EQUATOR Network. Reporting guidelines under development for systematic reviews: PRISMA-RR and PRISMA-P update records. Status checked 9 August 2026. EQUATOR under-development register.
  17. Centre for Reviews and Dissemination, University of York. PROSPERO: eligibility for inclusion. Status checked 9 August 2026. PROSPERO eligibility.
  18. Nussbaumer-Streit B, Klerings I, Dobrescu AI, et al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. J Clin Epidemiol. 2020;118:42-54. https://doi.org/10.1016/j.jclinepi.2019.10.011
  19. Haby MM, Barreto JOM, Kim JYH, et al. What are the best methods for rapid reviews of the research evidence? A systematic review of reviews and primary studies. Res Synth Methods. 2024;15:2-20. https://doi.org/10.1002/jrsm.1664
  20. Hamel C, Michaud A, Thuku M, et al. Defining rapid reviews: a systematic scoping review and thematic analysis of definitions and defining characteristics of rapid reviews. J Clin Epidemiol. 2021;129:74-85. https://doi.org/10.1016/j.jclinepi.2020.09.041

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *